Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

Daiichi Sankyo

Status and phase: Completed; Phase 4

Conditions: Acute Coronary Syndrome (ACS)

Treatments: Drug: Prasugrel

Study type: Interventional

Funder types: Industry

Identifiers

NCT03672097

CS747S-B-A4003

Details and patient eligibility

About

This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.

Enrollment: 204 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Is within the age limits and has signed informed consent

• Weighs at least 50 kg

• Had a previous diagnosis of ACS (UA, STEMI, or NSTEMI), underwent PCI, and received one of the following treatments:

  • Clopidogrel MD of 75 mg and aspirin 81-100 mg for 2-8 weeks following clopidogrel loading dose (LD) of 300 mg or 600 mg at the time of PCI
  • Ticagrelor MD of 90 mg twice daily (BID) and aspirin 81-100 mg for 1-4 weeks and switching to clopidogrel MD of 75 mg and aspirin 81-100 mg for 2-4 weeks following ticagrelor LD of 180 mg at the time of PCI
  • Clopidogrel MD 75 mg and aspirin 81-100 mg for 2-8 weeks following ticagrelor LD of 180 mg at the time of PCI
  • Or based on investigator's judgment with at least 2 weeks continued use of clopidogrel MD and aspirin 81-100 mg per day before switching to prasugrel and maximum 8 weeks P2Y12 inhibitors MD treatment (prasugrel is not allowed)

• Is willing and able to abide by the rules of the research unit and study restrictions

• If a woman of child-bearing potential, has a negative serum pregnancy test at screening

• Agrees to use at least one method of contraception during the study

Exclusion criteria

• Has active bleeding, significant risk of hemorrhage, or unusual susceptibility to bleed
• Had previous hemorrhagic stroke at any time, or transient ischemic attack (TIA) or ischemic stroke within 3 months before the informed consent date
• Has known allergies or hypersensitivity to prasugrel, aspirin, or any of their excipients
• Has significant hypertension at screening or baseline assessment
• Has hemoglobin levels <10.5 g/dL or hematocrit levels <30%
• Has severe left ventricular systolic dysfunction, ejection fraction <30%
• Is currently undergoing hemodialysis
• Has evidence of severe hepatic disease or any of the following: serum alanine transaminase or aspartate transaminase ≥3 times the upper limit of normal (ULN); or bilirubin ≥2 times the ULN at screening
• Has any clinical laboratory result performed at screening that is determined to be detrimental to the patient or could compromise the study as determined the Investigator
• Has previously participated in this study or in another interventional trial that is not compatible with this study
• Has evidence of significant active neuropsychiatric disease, alcohol abuse or drug abuse as determined by the Investigator

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

204 participants in 1 patient group

Prasugrel

Experimental group

Description:

Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)

Treatment:

Drug: Prasugrel